Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
CJC-1295 vs Mecasermin (Increlex)
An educational, source-based comparison of CJC-1295 and Mecasermin (Increlex) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic analog of growth hormone-releasing hormone (GHRH). The non-DAC version has a short half-life that preserves pulsatile GH release, while DAC variants extend the half-life via albumin binding. Research focuses on stimulating endogenous GH and IGF-1 production via the pituitary.
- Endogenous GH pulse amplitude
- IGF-1 elevation
- Body composition in adult GH-deficient research
- Sleep architecture (slow-wave sleep)
- • GH-axis manipulation may affect glucose tolerance.
- • Banned in competitive sport (WADA).
- • Requires physician oversight in any therapeutic context.
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.
- Severe primary IGF-1 deficiency
- Growth failure with GH gene deletion and neutralizing GH antibodies
- • FDA-approved.
- • Hypoglycemia — must be taken with food.
- • Tonsillar hypertrophy, intracranial hypertension reported.
CJC-1295 vs Mecasermin (Increlex) — Key differences
- Class: CJC-1295 is classified as Growth Hormone Axis, while Mecasermin (Increlex) is IGF-1 · Endocrine.
- Primary research focus: CJC-1295 — endogenous gh pulse amplitude; Mecasermin (Increlex) — severe primary igf-1 deficiency.
- Tag: Growth hormone vs FDA-Approved · Endocrine.